Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of Arfolitixorin, 5-Fluorouracil, Oxaliplatin, and Bevacizumab for Patients with Metastatic Colorectal Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called metastatic colorectal cancer, which is a form of cancer that starts in the colon or rectum and spreads to other parts of the body. The study is testing a new treatment combination that includes a medication called Arfolitixorin, along with other drugs: 5-fluorouracil, oxaliplatin, and bevacizumab. Arfolitixorin is a form of folate, a vitamin that helps cells grow and divide, and it is being tested to see if it can improve the effectiveness of the other cancer treatments.

The purpose of this study is to evaluate the safety and effectiveness of this combination treatment in patients who have not received any prior treatment for their metastatic colorectal cancer. The study is divided into two phases. In the first phase, the focus is on determining the safest dose of Arfolitixorin that can be given with the other drugs. In the second phase, the study will look at how well the treatment works in shrinking tumors and controlling the cancer.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor participants for any side effects and measure how the cancer responds to the treatment over time. The goal is to find out if this new combination can be a safe and effective option for treating metastatic colorectal cancer.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    The study begins with the administration of arfolitixorin in combination with other medications. These include 5-fluorouracil, oxaliplatin, and bevacizumab. The treatment is given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein.

    The purpose of this phase is to evaluate the safety and tolerability of the treatment combination. This involves monitoring for any side effects or reactions to the medications.

  2. Step 2

    Dose evaluation phase

    During this phase, two different doses of arfolitixorin are tested. One is the maximum tolerated dose, and the other is a lower dose. The goal is to determine which dose is more effective and better tolerated.

    The effectiveness of the treatment is assessed by measuring the response of the cancer to the medication. This is done using imaging techniques to see if the cancer has shrunk or stopped growing.

  3. Step 3

    Monitoring and follow-up

    Throughout the study, regular monitoring is conducted to track the progress of the treatment. This includes blood tests and other laboratory evaluations to check for any changes in health status.

    The study also measures the time until the disease progresses or until any adverse effects occur. This helps in understanding the long-term impact of the treatment.

  4. Step 4

    End of treatment evaluation

    At the end of the treatment period, a final evaluation is conducted. This includes assessing the overall response to the treatment and any side effects experienced.

    The results from this evaluation help in determining the overall success of the treatment and its potential for future use in similar cases.

Who can join the trial?

13 criteria

  • Sign an Informed Consent Form (ICF) and be able to follow the study requirements.
  • Have a life expectancy of more than 12 weeks.
  • Female patients must be surgically sterile, postmenopausal for at least 1 year, or have a negative pregnancy test result before starting the study treatment.
  • Female patients who can have children must agree to use effective birth control methods.
  • Male patients with female partners who can have children must agree to use effective birth control methods.
  • Have a confirmed diagnosis of a specific type of colorectal cancer that has spread to other parts of the body and is suitable for a particular treatment regimen.
  • Provide a sample of the tumor tissue for testing.
  • Have a healthy heart, with specific requirements for heart rate, blood pressure, and other heart function tests.
  • Have acceptable blood test results, including hemoglobin, white blood cells, and platelets.
  • Have proper organ function, with specific limits for liver and kidney tests.
  • Be at least 18 years old at the time of signing the consent form.
  • Have a disease that can be measured using imaging tests within 28 days before starting the treatment.
  • Have a good general health status, as measured by the Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, which indicates the ability to carry out daily activities.

Who cannot join the trial?

5 criteria

  • Patients who do not have metastatic colorectal cancer cannot participate. This is a type of cancer that has spread from the colon or rectum to other parts of the body.
  • Patients who are not within the specified age range cannot participate. The age range is typically defined by the study.
  • Patients who are not able to tolerate the study medications cannot participate. This means if the medications cause severe side effects, the patient may not be eligible.
  • Patients who are not able to follow the study procedures cannot participate. This means if a patient cannot attend appointments or follow instructions, they may not be eligible.
  • Patients who are part of a vulnerable population may not be eligible. This includes groups who may need special protection in research studies.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Arfolitixorin

    is a medication being studied for its potential to enhance the effectiveness of chemotherapy in treating metastatic colorectal cancer. It is used in combination with other cancer-fighting drugs to see if it can improve treatment outcomes.

  • 5-Fluorouracil

    is a chemotherapy drug that works by interfering with the growth and spread of cancer cells. It is commonly used to treat various types of cancer, including colorectal cancer.

  • Oxaliplatin

    is another chemotherapy medication that is used to treat colorectal cancer. It works by damaging the DNA of cancer cells, which prevents them from growing and dividing.

  • Bevacizumab

    is a type of medication known as a monoclonal antibody. It works by blocking a protein that helps cancer cells grow new blood vessels, which are needed for tumors to grow and spread. This can help slow down or stop the growth of cancer.

What is already known about the treatment

Arfolitixorin – Arfolitixorin is administered intravenously and is currently being studied in clinical trials for its use in treating metastatic colorectal cancer. It is being evaluated for safety, tolerability, and anti-tumor activity when combined with 5-fluorouracil, oxaliplatin, and bevacizumab. The medication works by enhancing the effectiveness of chemotherapy drugs through its role as a folate-based compound, which is crucial for DNA synthesis and repair. Arfolitixorin is classified as a folate analog and is being investigated to determine its optimal dosing and therapeutic potential in cancer treatment.

Investigated diseases

Metastatic Colorectal Cancer – This is a type of cancer that begins in the colon or rectum and has spread to other parts of the body, such as the liver or lungs. It typically starts as a growth, called a polyp, on the inner lining of the colon or rectum, which can become cancerous over time. As the cancer progresses, it can invade nearby tissues and spread through the lymphatic system or bloodstream to distant organs. The progression of the disease can vary, with some patients experiencing rapid spread, while others may have a slower progression. Symptoms may include changes in bowel habits, blood in the stool, abdominal pain, and unexplained weight loss. The disease is often diagnosed at an advanced stage due to the subtlety of early symptoms.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-516802-43-00Protocol codeISO-CC-010Estimated enrolment90 patientsSponsorIsofol Medical AB (publ)

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.